Evidence map›Paper›PMID 41626181›Full record

ArticleFrontiers in oncology2025

Identify and validate a novel ubiquitination-related biomarker for thyroid cancer prognosis and immunotherapy.

Yilin Li, Jutao Zeng, Xiongmeiyu Gong, Wei Li, Jueli Liu, Dan Li, Yangyan Zhong, Junjie Deng, Jian Deng, Haigang Feng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yilin Li *Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jutao Zeng *Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xiongmeiyu Gong *Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wei LiDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jueli LiuSchool of Medicine, Hunan Normal University, Changsha, Hunan, China.
Dan LiDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yangyan ZhongDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Junjie DengDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jian DengDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Haigang FengDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jie LuoDepartment of Anesthesiology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hong CaoDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ubiquitination is a critical protein modification process that plays a pivotal role in maintaining cellular homeostasis and is implicated in various pathophysiological processes, including thyroid cancer (THCA). Understanding the roles of ubiquitination-related genes in THCA progression and their interactions with the tumor microenvironment (TME) could provide valuable insights into prognosis and treatment strategies. Methods: Using iUUCD 2.0, ubiquitination-related genes were identified and subjected to consensus clustering on TCGA-THCA data. Differentially expressed genes (DEGs) between tumor and normal tissues were identified and used to construct a ubiquitination-related signature using Cox and LASSO regression. The signature's prognostic ability was validated using training and test datasets from TCGA. Immune cell infiltration, immunotherapy response, and drug sensitivity were analyzed. Results: Three ubiquitination clusters were identified among 454 genes. Four prognostic DEGs (F12, FBXO15, FBXW10, and USP44) formed the signature, significantly correlating with survival, immune cell infiltration, clinical characteristics, immune checkpoints, immunotherapy response, and drug sensitivity. Low-risk THCA patients had better prognosis and immunotherapy responses than high-risk patients. A stable nomogram combining the signature and clinical characteristics predicted patient survival. RT-qPCR and immunohistochemistry confirmed differential expression of key genes. Conclusion: Our study identifies and validates a novel four-gene ubiquitination-related signature as a promising and independent prognostic biomarker in THCA. Beyond outcome prediction, this signature demonstrates significant translational potential by accurately predicting immunotherapy responses, thereby facilitating the development of more personalized and effective treatment strategies for patients with THCA.

Indexed as

immunotherapyprognosisthyroid cancertumor microenvironmentubiquitination

Identifiers

PMID41626181
PMCPMC12855127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.